Co-diagnostics, inc. announces recent grant awards

The company intends to use funds awarded by the bill & melinda gates foundation toward completion of tuberculosis and hpv tests for its co-dx pcr home™ platform  salt lake city , july 18, 2023 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company" or "co-dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced grants awarded by the bill & melinda gates foundation related to the tuberculosis (tb) and human papillomavirus (hpv) tests on the company's co-dx pcr home™ platform. co-dx intends to use funds awarded by the gates foundation toward completion of tb and hpv tests for its new platform the tb and hpv grants in the amounts of $1.33 million and $987,000 respectively will be applied towards completion of these tests, intended for priority global markets.
CODX Ratings Summary
CODX Quant Ranking